Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report) and Aerovate Therapeutics (AVTE – Research Report).
Incyte (INCY)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Incyte, with a price target of $95.00. The company’s shares closed last Friday at $82.34, close to its 52-week high of $84.86.
According to TipRanks.com, Goldstein is a 3-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Hold with an average price target of $84.00.
See the top stocks recommended by analysts >>
Aerovate Therapeutics (AVTE)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Aerovate Therapeutics, with a price target of $54.00. The company’s shares closed last Friday at $24.79, close to its 52-week high of $27.83.
According to TipRanks.com, Argyrides has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Aerovate Therapeutics is a Moderate Buy with an average price target of $40.50, implying a 59.4% upside from current levels. In a report issued on December 6, BTIG also upgraded the stock to Buy with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INCY:
